Johnson & Johnson has entered into a definitive agreement to acquire Actelion Ltd. for approximately $30 billion in cash. The transaction was unanimously approved by the boards of both companies. Johnson & Johnson will fund the transaction with cash held outside the U.S.   Actelion, based in Allschwil, Switzerland, has a franchise of differentiated, innovative products for pulmonary arterial hypertension (PAH), as well as specialty in-market medicines and late-stage products. J&J e...